Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2305 - Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Cytotoxic Therapy;  Radiation Oncology

Tumour Site


Yuichi Takiguchi


Annals of Oncology (2018) 29 (suppl_8): viii488-viii492. 10.1093/annonc/mdy291


Y. Takiguchi1, K. Yamada2, H. Tanaka3, K. Kubota4, K. Kishi5, T. Shimokawa6, H. Saito7, Y. Hosomi8, T. Kato7, N. Nogami9, S. Igawa10, T. Kasai11, Y. Nakamura12, T. Yamanaka13, H. Okamoto14

Author affiliations

  • 1 Medical Oncology, Chiba University, School of Medicine, 260-8677 - Chiba/JP
  • 2 Respirology, Neurology, And Rheumatology, Kurume University, 830-0011 - Kurume/JP
  • 3 Thoracic Oncology, Niigata Cancer Center, Niigata/JP
  • 4 Division Of Pulmonary Medicine And Oncology, Nippon Medical School, 113-8603 - Tokyo/JP
  • 5 Respiratory Medicine, Toranomon Hospital, 105-8470 - Tokyo/JP
  • 6 Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 240-8555 - Yokohama/JP
  • 7 Department Of Thoracic Oncology, Kanagawa Cancer Center, Yokohama/JP
  • 8 Department Of Thoracic Oncology & Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-0021 - Tokyo/JP
  • 9 Thoracic Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 10 Respiratory Medicine, Kitasato University School of Medicine, 252-0374 - Kanagawa/JP
  • 11 Respiratory Medicine, Tochigi Cancer Center, 320-0834 - Utsunomiya/JP
  • 12 Respiratory Medicine, Tochigi Cancer Center, Utsunomiya/JP
  • 13 Biostatistics, Yokohama City University Hospital, 236-004 - Yokohama/JP
  • 14 Respiratory Medicine And Medical Oncology, Yokohama Municipal Citizen's Hospital, 240-8555 - Yokohama/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2305


Treatment with an immune checkpoint inhibitor (ICI) on completion of concurrent chemoradiotherapy (CCRT) for pts with inoperable stage III NSCLC significantly prolongs the PFS; however the best chemotherapy regimen in CCRT has not been established. This study was conducted to evaluate whether SP or DP, both with concurrent thoracic radiotherapy, in pts with inoperable stage III NSCLC showed a favorable 2-year OS rate with less toxicity in the SP arm as presented previously (J Clin Oncol 2017; 35, suppl; abstr 8534). An update of survival, relapsed sites and post-treatment information with prolonged follow-up has been awaited.


Pts with inoperable stage III NSCLC were randomized to SP (S-1 40 mg/m2 bid on days 1-14 and 29-42 plus cisplatin 60 mg/m2 on days 1 and 29) or DP (docetaxel 50 mg/m2 and cisplatin 80 mg/m2 on days 1 and 29), with concurrent radiotherapy beginning on day 1 (60 Gy/30 fr) followed by two additional cycles of the chemotherapy. Primary endpoint was 2-year OS rate, and secondary endpoints included OS, PFS and safety.


Among 110 pts enrolled, 106 (53 in each arm) were evaluable, with male/female 83/23; median age 65 (range 42-74); performance status 0/1 59/47; IIIA/IIIB 59/47. With a median follow-up of 48.1 months, 2-year survival and median OS were 79% (95% CI: 68-90%) and 55.2 months in the SP and 69% (95% CI: 57-82%) and 50.8 months in the DP arm, respectively. 5-year PFS rates in SP and DP arms were 23.2 (95% CI: 11-35) and 23.6% (95% CI: 11-36), and 5-year OS rates were 48.8 (95% CI: 34-64) and 42.3% (95%CI: 24-61), respectively. Hematological and non-hematological toxicities were less in the SP arm. Relapsed site in the RT field and in the CNS were similar between the two arms. Post-treatment chemotherapy for pts with progression was delivered in 92.5% and 71.1% pts in SP and DP arms, respectively.


Because of favorable 2-year OS with less toxicity, we choose SP in CCRT as a future reference regimen. High 5-year PFS and OS rates shown here should be considered in designing further studies where CCRT is followed by ICI.

Clinical trial identification


Legal entity responsible for the study

NPO Thoracic Oncology Research Group (TORG).


Has not received any funding.

Editorial Acknowledgement


Y. Takiguchi, K. Yamada, K. Kubota, K. Kishi, Y. Hosomi, T. Kato, N. Nogami, T. Kasai, Y. Nakamura, T. Yamanaka, H. Okamoto: Lecture fee, Research funds: Taiho Pharmaceutical Co. H. Tanaka, T. Shimokawa, H. Saito, S. Igawa: Lecture fee: Taiho Pharmaceutical Co.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.